If FLASH dose rates have the potential to reduce TGF-β induction not only in normal tissues compared to CONV dose rates but also within the tumor microenvironment (TME), cancer cells would become more radiosensitive and tumor control could be improved (Figure 1). The gene discussed is TGFB1; the disease is cancer.